Real-world study of remazolam vs midazolam in sedation of patients with renal insufficiency in ICU

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039513

Enrollment

Unknown

Registered

2020-10-30

Start date

2020-10-30

Completion date

Unknown

Last updated

2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney injury

Interventions

Remazolam:Remazolam sedation

Midazolam:Midazolam

Eligibility

Sex/Gender

All

Age

15 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who meet the diagnostic criteria of AKI or CKD and whose initial creatinine clearance rate is less than 80ml/min, who are 15 years old and older and whose length of stay in the ICU are more than 48h.

Exclusion criteria

Exclusion criteria: Patients with liver dysfunction and advanced tumors.

Design outcomes

Primary

Measure	Time frame
eGFR;	—

Secondary

Measure	Time frame
rass score;Mechanical ventilation time;90-day mortality;Wake-up time;	—

Countries

China

Contacts

Public ContactZhou Liangliang

Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School /The First People's Hospital of Yancheng

zholia@126.com+86 18260087965

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026